Tal Ben-Ami

Tal Ben-Ami

Auto-generated profile, based on publicly available information

Tal Ben-Ami

Pediatric Hematology Unit, Kaplan Medical Center, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in The Journal of Pediatrics
Verified
Journal Article
Closed access
TBTal Ben-Ami
Tal Ben-Ami
SRShoshana Revel-Vilk
Shoshana Revel-Vilk
RBRebecca Brooks
Rebecca Brooks
ASAvraham Shaag
Avraham Shaag
MHMichael S. Hershfield
Michael S. Hershfield
PSPolina Stepensky
Polina Stepensky

14 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KSKris Ann P. Schultz
Kris Ann P. Schultz
ANAlexander T. Nelson
Alexander T. Nelson
PMPaige H. R. Mallinger
Paige H. R. Mallinger
AHAnne K. Harris
Anne K. Harris
JKJunne Kamihara
Junne Kamihara
YMYoav H. Messinger
Yoav H. Messinger
Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the goals of the Registry is to continue to refine these guidelines as additional data become available. Experimental Design: Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the NCI Natural History of DICER1 Syndrome study. Results: Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli–Leydig cell tumor at a median age of 14 years (range: 11 months–66 years); 13% were diagnosed before 8 years of age, the current age of onset of pelvic surveillance. Additionally, 4% of Sertoli–Leydig cell tumors were diagnosed before 4 years of age. Conclusions: Ongoing data collection highlights the role of lung surveillance in the early detection of PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before 8 years of age, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.

1 November 2013 in The Journal of Pediatrics
Verified
Journal Article
Closed access
SRShoshana Revel-Vilk
Shoshana Revel-Vilk
JYJoanne Yacobovich
Joanne Yacobovich
SFShlomzion Frank
Shlomzion Frank
TBTal Ben-Ami
Tal Ben-Ami
MYMichal Yechieli
Michal Yechieli
HTHannah Tamary
Hannah Tamary

26 June 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
AFAndrea Ferrari
Andrea Ferrari
Dominik SchneiderDominik Schneider
Dominik Schneider
GBGianni Bisogno
Gianni Bisogno
YRYves Reguerre
Yves Reguerre
JGJan Godzinski
Jan Godzinski
IBInes B. Brecht
Ines B. Brecht
It has become increasingly clear in recent years that we need to develop ad hoc strategies to combat very rare tumors (VRT) of pediatric age. In 2008, several schemes being run in different countries were pooled together to create the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) project: a cooperative study group that aimed to promote research in the relatively uncharted territory of rare tumors of pediatric age. EXPeRT members were able to activate different levels of cooperation to achieve their goals, and to obtain dedicated funding by participating in EU‐financed projects. Their experiences emphasize the merits of networking, seeking new partnerships, joining forces, and pooling resources to extend the reach of research efforts, and ultimately improve the quality of patient care. Between 2018 and 2021, the EXPeRT has been active in establishing the Pediatric Rare Tumors Network ‐ European Registry (PARTNER). This project had the main purposes of building a European common registry of pediatric VRT, but also the major task of developing diagnostic and treatment guidelines for VRT (or at least part of them). These clinical recommendations are the subject of a series of papers on Pediatric Blood and Cancer.

24 March 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
Dominik SchneiderDominik Schneider
Dominik Schneider
DODaniel Orbach
Daniel Orbach
TBTal Ben‐Ami
Tal Ben‐Ami
EBEwa Bien
Ewa Bien
GBGianni Bisogno
Gianni Bisogno
BFBrice Fresneau
Brice Fresneau

12 April 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
TBTal Ben‐Ami
Tal Ben‐Ami
UKUdo Kontny
Udo Kontny
ASAurore Surun
Aurore Surun
IBInes B. Brecht
Ines B. Brecht
RARicardo López Almaraz
Ricardo López Almaraz
DODaniel Orbach
Daniel Orbach